Medtronic’s Strategic Shift

Summary

Medtronic is spinning off its diabetes business into a new independent company, while simultaneously grappling with a substantial tariff impact of up to $350 million. This move allows Medtronic to focus on high-growth markets and improve its profit margins, while the new diabetes company gains the autonomy to pursue its own innovations. The spinoff, expected within 18 months, marks a significant restructuring for Medtronic and raises questions about the future of both entities.

Safeguard patient information with TrueNASs self-healing data technology.

** Main Story**

Medtronic announced on May 21, 2025 that it will spin off its diabetes business into a separate, independent company. This decision comes as the medical device giant anticipates a significant financial impact from tariffs, estimated to reach up to $350 million. While the diabetes division has recently seen a resurgence in growth, Medtronic believes this strategic move will allow both entities to thrive independently.

Diabetes Division Spin-off: A Strategic Restructuring

Medtronic’s diabetes business, currently led by Que Dallara, will become an independent, publicly traded company, preferably through an initial public offering (IPO). This new company will encompass 8,000 employees worldwide, along with the existing diabetes product portfolio, pipeline, intellectual property, and manufacturing facilities. Dallara, who will become the CEO of the new company, emphasized the “extremely robust pipeline” and focus on improving patient outcomes by lowering A1C levels. The spin-off aims to provide the diabetes division with greater focus and resources to accelerate innovation in the rapidly evolving diabetes technology market, while also streamlining Medtronic’s overall portfolio.

This separation marks a strategic shift for Medtronic, allowing the company to concentrate on core, high-growth areas such as cardiovascular devices, neuroscience technology, and medical-surgical tools. CEO Geoff Martha believes the spinoff will be a “win-win,” leading to higher profit margins for Medtronic and increased focus for the diabetes business. This strategic move follows a trend of streamlining within Medtronic, including their exit from the ventilator market in 2024 and the formation of a separate kidney care-focused company with DaVita in 2023. Analysts have expressed some reservations about the timing of the spinoff, given the diabetes division’s recent turnaround and growth.

Tariff Troubles and Mitigation Efforts

Medtronic anticipates tariffs to impact its business significantly, estimating a cost between $200 million and $350 million for the next fiscal year. This projection depends on the potential reinstatement of tariffs on China after a 90-day pause. Medtronic’s tariff concerns stem primarily from duties impacting its exports to China, rather than imports from China. The company generates 60% of its revenue from US-made products, with a majority of its research and development also based in the US. Medtronic is working to mitigate the effects of these tariffs through several strategies:

• Seeking humanitarian exemptions to import taxes.
• Rerouting logistics flows.
• Controlling discretionary costs.

While long-term adjustments to manufacturing locations are under consideration, they are not currently a viable short-term solution due to the time required for such changes. Medtronic has faced tariff challenges in the past, with executives citing tariffs as contributing to increased costs in 2019. The company is in communication with the current administration and, through its affiliation with the industry trade group AdvaMed, advocates for broader exemptions from import tariffs. Despite exemptions for other product categories, the administration has yet to grant relief for medical devices.

Looking Ahead: Growth Projections and Strategic Focus

Despite the anticipated tariff impact, Medtronic projects roughly 5% organic revenue growth in the new fiscal year, slightly exceeding analyst expectations. This growth will primarily come from the company’s atrial fibrillation and hypertension businesses. Medtronic aims to restore high single-digit earnings growth by 2027. The diabetes spinoff further supports this goal. The separation is expected to be accretive to Medtronic’s earnings, operating margin, and gross margin immediately upon completion. This move simplifies Medtronic’s portfolio, allowing for greater focus on higher-margin growth drivers, while creating a new, independent player in the diabetes technology space.

Medtronic’s strategic decisions, both in spinning off its diabetes division and navigating tariff challenges, reflect the company’s commitment to adapting to a dynamic global market. While the long-term effects of these decisions remain to be seen, they position Medtronic and the new diabetes company for independent growth and innovation in the medical technology field.